PULIKE: 265 million idle fundraising cash management matures, recovering principal of 821 million with earnings of 3.6653 million

In August-September 2024, PULIKE Biotechnology Co., Ltd. plans to conduct cash management for temporarily idle raised funds not exceeding 265 million yuan, subject to review. The usage period is valid for 12 months from the date of approval at the third extraordinary general meeting of shareholders in 2024. On August 22, 2025, the company will fully redeem the idle raised funds under cash management upon maturity and return them to the designated account